[Drug therapy of pre-excitation syndromes].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000404:Ajmaline / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D013577:Syndrome; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000404:Ajmaline; D008012:Lidocaine; D014700:Verapamil; D011802:Quinidine
La terapia farmacologica delle sindromi di preeccitazione.